A phase I/II First-In-Human therapeutic trial with 177Lu-BetaBart in multiple tumor types
Latest Information Update: 18 Oct 2024
Price :
$35 *
At a glance
- Drugs RV 01 Radiopharm Ventures (Primary)
- Indications Cancer
- Focus Adverse reactions; First in man
- 18 Oct 2024 New trial record
- 15 Oct 2024 According to an AtomVie Global Radiopharma media release, phase I/II First-In-Human therapeutic trial with 177Lu-BetaBart in multiple tumor types in the US, is expected for mid-2025.